P378 Immunisation practices for hepatitis B and response to vaccination in Greek patients with inflammatory bowel disease

Kalogera, Despina; Siakavellas, Spyros I.; Zambeli, Evanthia; Tsironi, Eftychia; Tzouvala, Maria; Moschovis, Dimitrios; Kostas, Athanasios; Axiaris, Georgios; Kourkoutas, Elias; Filippakou, K; Vlachogiannakos, Jiannis; Michopoulos, Spyros; Papatheodoridis, George; Bamias, G

doi:10.1093/ecco-jcc/jjx180.505

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After reviewing the full texts, 21 studies were included for the analysis 7,17–36 . Details of excluded studies are provided in Table S2 37–51 . Of the included studies, 17 were full articles 7,17–26,29,31–35 and 4 were published as abstracts 27,28,29,31 .…”

Section: Resultsmentioning

confidence: 99%

“…7,[17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36] Details of excluded studies are provided in Table S2. [37][38][39][40][41][42][43][44][45][46][47][48][49][50][51] Of the included studies, 17 were full F I G U R E 1 PRISMA flowchart showing the selection of studies for the systematic review articles 7,[17][18][19][20][21][22][23][24][25][26]29,[31][32][33]…”

Section: Re Sultsmentioning

confidence: 99%

See 1 more Smart Citation

Meta‐analysis: hepatitis B vaccination in inflammatory bowel disease

Singh

Jena

Mahajan

et al. 2022

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Background:The response rate of hepatitis B virus (HBV) vaccination in patients with inflammatory bowel disease (IBD) is variable. Increasing dose or accelerated schedule is the suggested strategy to improve seroconversion. Aim:We performed a meta-analysis to determine the pooled response rate of HBV vaccination and to identify the predictors of seroconversion. Methods:We searched PubMed, Embase and Cochrane library databases. Studies reporting the response of HBV vaccination in IBD patients were included. Response was recorded as adequate immune response (AIR, >10 IU/L) and Effective immune response (EIR, >100 IU/L). Pooled AIR and EIR rates were calculated for different doses (10-20 μg or 40 μg) and schedules (standard: 0, 1 and 6 months or accelerated: 0, 1 and 2 months). Meta-analysis was performed to identify the predictors of response.Results: Twenty-one studies including 2602 patients were eligible. Pooled AIR and EIR rates after HBV vaccination were 62% (95% CI, 55-68) and 42% (95% CI, 37-48), respectively. Pooled AIR and EIR rates for standard and double dose were similar.Pooled AIR and EIR rates were also comparable for different schedules of HBV vaccination. Gender, IBD subtype and disease activity did not affect the response rate.Use of immunosuppression [immunomodulators (RR: 0.73, 95% CI, 0.62-0.87) and anti-TNFs (RR: 0.72, 95% CI, 0.60-0.87)] was a predictor of poor immune response compared to no immunosuppressive therapy. Conclusion:Patients with IBD have a poor serological response after HBV vaccination. HBV screening and vaccination should preferably be done before starting the immunosuppressive drugs.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Re Sultsmentioning

confidence: 99%

Meta‐analysis: hepatitis B vaccination in inflammatory bowel disease

Singh

Jena

Mahajan

et al. 2022

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Hepatitis-B Vaccine Response in Inflammatory Bowel Disease Patients: A Systematic Review and Meta-analysis

Kochhar

Mohan

Khan

et al. 2021

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Background Data on efficacy of hepatitis-B vaccine (HBV) in patients with inflammatory bowel disease (IBD) is limited. Our aim was to review the literature and perform meta-analysis of available studies to quantify efficacy of HBV in patients with IBD. Methods We conducted a comprehensive search of several databases (inception to July 2020) to identify studies evaluating efficacy of HBV in patients with IBD. Random effects model was used to calculate the pooled rates and I2 percentage values were used to assess the heterogeneity. Results A total of 14 studies (2375 patients) were included. Four data sets were available from 2 studies that compared HBV response in patients with IBD against healthy controls. The pooled odds ratio of HBV response in IBD patients was 0.13 (95% CI, 0.05–0.33, P = 0.001). The pooled proportion of adequate immune response (AIR) was 64% (95% CI, 55–72.1, P = 0.003) from 13 data sets, and effective immune response (EIR) was 39.7% (95% CI, 30.7–49.5, P = 0.04) from 10 data sets. Conclusion Patients with IBD on immunosuppression demonstrated significantly reduced HBV response as compared with general population.

show abstract

P378 Immunisation practices for hepatitis B and response to vaccination in Greek patients with inflammatory bowel disease

Cited by 2 publications

References 0 publications

Meta‐analysis: hepatitis B vaccination in inflammatory bowel disease

Meta‐analysis: hepatitis B vaccination in inflammatory bowel disease

Hepatitis-B Vaccine Response in Inflammatory Bowel Disease Patients: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About